Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing itself at it
The model's full reasoning — Q3 2018 call → NOWe need answer only YES or NO. Need analyze transcript for identifiable offering with both conditions: customer response running ahead of prepared, and company responding now by putting more behind it. Also offering still small relative to total business. Let's parse. Management discusses TIBSOVO launch. Steve: "pleased with progress of U.S. launch" "first quarterly TIBSOVO launch update, net U.S. sales $4.5 million for first partial quarter." "Since launch in July, team ... approximately 2,000 customer interactions" "increasing testing rates... encouraged with steady growth" "awareness of TIBSOVO already above 90%, compares favorably to 50% awareness of IDHIFA at similar time" "During first two months, estimate over 100 unique prescribers" "pleased with uptake" "reimbursement... pleased with payer response" "not aware of any payer-related coverage issues." Does this indicate customer response running ahead of what company prepared for? They compare to IDHIFA, but do they say demand exceeded prepared? They say "awareness already above 90% compares favorably" and "testing rates" but not necessarily ahead of plan. They don't say they had prepared for less. They say "we are pleased" but no explicit gap between response and preparation. Also company responding by putting more behind it? They don't describe adding capacity, staff, investment. They say field team has had interactions, but no expansion. They say "we don't have any immediate plans to scale up that organization" in response to question. So no. Other offerings? AG-270? No. Mitapivat? Enrollment expected complete 2019, no demand ahead. AG-881? No. TIBSOVO sNDA? Not customer response. IDHIFA? Established. Thus answer NO. Need only YES or NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
HCKT · Q1 2024 → YESThe question is about whether management describes one identifiable offering that's still small, where customer response is ahead of what they prepared for, AND they're responding now by putting more ...YES The transcript describes AI Explorer (the GenAI assessment platform) as a small, early-stage offering (nominal Q1 revenue impact, part of broader GenAI pivot). Management states customer response is exceeding preparation: "over 175 demo meetings with many more scheduled... resulted in a number of new enterprise...
SYY · Q1 2023 → YESThe question is about whether management describes one identifiable offering or initiative that's still a smaller part of the business, where customer response is running ahead of what they prepared f...YES The transcript shows that Sysco Your Way is presented as a smaller, still-developing offering (described as part of the Recipe For Growth pillars, with its scale expected to grow each quarter and currently limited to specific neighborhoods and recent international rollouts like Toronto and Dublin).
PRPH · Q1 2023 → YESThe question asks if management describes one identifiable offering that's still a smaller part of the business, where customer response is running ahead of what they prepared for, AND they're respond...YES The lozenge manufacturing facility is the clearest match. It is explicitly described as “the least interesting business we’re developing” and still a smaller slice of overall results (COVID testing was the dominant revenue driver for the prior two years).